NCT02059642 - A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions

ADHDAttention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type

Interventions

DRUG

MG01CI (1400 mg)

MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily

DRUG

placebo

Placebo 1400 mg administered orally once daily

Trial Locations (20)

10549

Bioscience Research, Mount Kisco

19063

Sequoia Behavioral Healthcare, Media

20170

NeuroScience, Inc. (NSI), Herndon

21144

Pediatric Psychopharmacology & Adult ADHD Program, Massachusetts General Hospital, Boston

27609

Richard H Weisler, MD, PA, Raleigh

27705

Duke University, Durham

32607

Sarkis Clinical Trials, Gainesville

33173

Miami Research, South Miami

40509

University Kentucky Psychiatry, Lexington

48083

Behavioral Medicine Center, Troy

48307

Rochester Center For Behavioral Medicine, Rochester Hills

60048

Capstone Clinical Research, Libertyville

63301

St. Charles Psychiatric Associates, Saint Charles

66211

Psychiatric Associates, Overland Park

75231

FutureResearch Trials Dallas, LP, Dallas

77007

Bayou City Research, Houston

78731

FutureResearch Trials, Austin

89128

Center for Psychiatry and Behavioral Medicine, Las Vegas

Unknown

Neurocognitive unit Rambam MC, Haifa

ADHD unit Geha MC, Petah Tikva

All Listed Sponsors

lead

Alcobra Ltd.

INDUSTRY